marie wislez
机构: Professeur des Université Praticien Hospitalier
每年引用次数
引用次数
引用: 14,169
H-指数: 63
I10-指数 : 158
出版物: 659
Molecular classification of pulmonary sarcomatoid carcinomas suggests new therapeutic opportunities
N. Pécuchet , T. Vieira , N. Rabbe , M. Antoine
Annals of Oncology 28 ( 7) 1597 -1604
20
2017
Crizotinib in c-MET- or ROS1-positive NSCLC: results of the AcSé phase II trial
D. Moro-Sibilot , N. Cozic , M. Pérol , J. Mazières
Annals of Oncology 30 ( 12) 1985 -1991
48
2019
Upregulation of bronchioloalveolar carcinoma-derived C-X-C chemokines by tumor infiltrating inflammatory cells.
M. Wislez , C. Philippe , M. Antoine , N. Rabbe
Inflammation Research 53 ( 1) 4 -12
25
2004
FRI0460 Pulmonary Fibrosis in Anca-Associated Vasculitis: Clinical Characteristics and Long-Term Followup of 49 Patients
C Comarmond , B Crestani , A Tazi , B Hervier
Annals of the Rheumatic Diseases 73 553 -554
1
2014
IFCT0401-bio trial: Pathological and EGF-r molecular analysis of tumor-biopsy samples from patients with non-resectable, pneumonic-type adenocarcinoma (P-ADC) treated by gefinitib. Preliminary results from surgical specimens
J. Cadranel , M. Wislez , F. Coulet , V. Poulot
Journal of Clinical Oncology 24 7185 -7185
2006
Effet de la stimulation du récepteur Toll de type 9 au cours des adénocarcinomes pulmonaires mutés pour K-RAS
L. Belmont , N. Rabbe , V. Poulot , M. Antoine
Revue Des Maladies Respiratoires 25 ( 9) 1171
2008
Analyse immunohistochimique des voies de survie mises en jeu dans des adénocarcinomes bronchiques
B. Busser , E. Brambilla , D. Moro , J.-L. Coll
Revue Des Maladies Respiratoires 25 ( 9) 1170
2008
Évaluation d’une technique d’IRM thoracique pour l’étude d’un modèle murin d’adénocarcinome pulmonaire muté pour RAS
L. Belmont , N. Rabbe , C.D. Thomas , V. Poulot
Revue Des Maladies Respiratoires 25 ( 9) 1172
2008
Bevacizumab et actes invasifs : recommandations pratiques
V. Gounant , B. Milleron , J. Assouad , J. Gligorov
Revue Des Maladies Respiratoires 26 ( 2) 221 -226
9
2009
Cancer bronchique du sujet âgé
G. Albrand , E. Biron , I. Boucot , L.J. Couderc
Revue Des Maladies Respiratoires 24 ( 6) 703 -723
5
2007
Valeur diagnostique de la mésothéline
M. Wislez
Revue Des Maladies Respiratoires 24 73 -74
2007
Thérapeutiques ciblées des stades métastatiques
M. Wislez
Revue Des Maladies Respiratoires 24 70 -72
2007
Efficacy of immune checkpoint inhibitors in lung sarcomatoid carcinoma: Data from a French multicentric cohort
C. Domblides , I. Monnet , J. Mazieres , F. Barlesi
Annals of Oncology 29
6
2018
Circulating tumor DNA (ctDNA) in advanced non-small cell lung cancer (NSCLC) from HIV-infected patients is associated to shorter overall survival (OS): Results from phase II trial (IFCT-1001 CHIVA)
M. Wislez , H. Blons , C. Domblides , F. Barlesi
Annals of Oncology 29
2018
Joined analysis of sarcomatoid carcinoma (SC) mutational profiles: Comparison of lung versus head and neck cancer
N. Pecuchet , R. Touachi , A. Ben Lakhdar , V. Fallet
Annals of Oncology 29
2018
Lung cancer patients with HER2 mutations treated with chemotherapy and HER2-targeted drugs: results from the European EUHER2 cohort
A. Cortot , D. Moro-Sibilot , J. Milia , O. Gautschi
Annals of Oncology 27 ( 2) 281 -286
266
2016
P1.13-09 Efficacy and Tolerance of Osimertinib in Real Word Setting: Results of the French Early Access Program (EXPLORE T790M GFPC Study)
J.B. Auliac , M. Pérol , D. Planchard , I. Monnet
Journal of Thoracic Oncology 13 ( 10)
1
2018
OA12.03 Activity of Crizotinib in MET or ROS1 Positive (+) NSCLC: Results of the AcSé Trial.
D. Moro-Sibilot , N. Cozic , M. Pérol , J. Otto
Journal of Thoracic Oncology 13 ( 10)
13
2018
[MET exon 14 splicing sites mutations: A new therapeutic opportunity in lung cancer].
S. Baldacci , Z. Kherrouche , C. Descarpentries , M. Wislez
Revue Des Maladies Respiratoires 35 ( 8) 796 -812
4
2018
Inhibiteurs du check-point immunitaire en néo-adjuvant dans les cancers bronchiques non à petites cellules localisés : essai IoNESCO
X. Mignard , M. Antoine , D. Moro-Sibilot , C. Dayen
Revue Des Maladies Respiratoires 35 ( 9) 983 -988
2
2018